Journal of the American Society of Hypertension
Volume 4, Issue 5 , Pages 227-235 , September 2010

Endothelin-1 response to glucose and insulin among African Americans

  • Stephanie DeLoach, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    • ,
  • Yonghong Huan, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    • ,
  • Constantine Daskalakis, ScD

      Affiliations

    • Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    • ,
  • Bonita Falkner, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    • Corresponding Author InformationCorresponding author: Bonita Falkner, MD, Division of Nephrology, Thomas Jefferson University, 833 Chestnut Street, Suite 700, Philadelphia, PA 19107. Tel: (215) 503-2501; fax: (215) 503-2506.

Received 7 April 2010 ,Accepted 31 July 2010.

References 

  1. Campia U, Cardillo C, Panza JA. Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation. 2004;109:3191–3195
  2. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28:652–655
  3. Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A, et al. Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes. 1995;44:431–436
  4. Evans RR, Phillips BG, Singh G, Bauman JL, Gulati A. Racial and gender differences in endothelin-1. Am J Cardiol. 1996;78:486–488
  5. Svetkey LP, Simons-Morton D, Vollmer WM, Appel LJ, Conlin PR, Ryan DH, et al. Effects of dietary patterns on blood pressure: Subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999;159:285–293
  6. Hattori Y, Kasai K, Nakamura T, Emoto T, Shimoda S. Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Metabolism. 1991;40:165–169
  7. Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C, et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab. 1995;80:829–835
  8. Takahashi K, Ghatei MA, Lam HC, O’Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 1990;33:306–310
  9. Cheng C, Kushner H, Falkner BE. The utility of fasting glucose for detection of prediabetes. Metabolism. 2006;55:434–438
  10. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214–E223
  11. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol. 1981;240:E630–E639
  12. Falkner B, Kushner H, Tulenko T, Sumner AE, Marsh JB. Insulin sensitivity, lipids, and blood pressure in young American blacks. Arterioscler Thromb Vasc Biol. 1995;15:1798–1804
  13. Yamauchi T, Ohnaka K, Takayanagi R, Umeda F, Nawata H. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett. 1990;267:16–18
  14. Leyva F, Wingrove C, Felton C, Stevenson JC. Physiological hyperinsulinemia is not associated with alterations in venous plasma levels of endothelin-1 in healthy individuals. Metabolism. 1997;46:1137–1139
  15. Metsarinne K, Saijonmaa O, Yki-Jarvinen H, Fyhrquist F. Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. Metabolism. 1994;43:878–882
  16. Ak G, Buyukberber S, Sevinc A, Turk HM, Ates M, Sari R, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. J Diabetes Complications. 2001;15:150–157
  17. Zanatta CM, Gerchman F, Burttet L, Nabinger G, Jacques-Silva MC, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80:299–304
  18. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol. 2006;17:943–955
  19. Ohta K, Hirata Y, Shichiri M, Kanno K, Emori T, Tomita K, et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int. 1991;39:307–311
  20. Dhaun N, Lilitkarntakul P, Macintyre IM, Muilwijk E, Johnston NR, Kluth DC, et al. Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol. 2009;296:F1477–F1483
  21. Tharaux PL, Hagege I, Placier S, Vayssairat M, Kanfer A, Girot R, et al. Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant. 2005;20:2408–2413
  22. Grenda R, Wuhl E, Litwin M, Janas R, Sladowska J, Arbeiter K, et al. Urinary excretion of endothelin-1 (ET-1), transforming growth factor- beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: Results of the ESCAPE trial. Nephrol Dial Transplant. 2007;22:3487–3494
  23. Langleben D, Dupuis J, Langleben I, Hirsch AM, Baron M, Senecal JL, et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest. 2006;129:689–695
  24. Brunner F, Doherty AM. Role of ET(B) receptors in local clearance of endothelin-1 in rat heart: Studies with the antagonists PD 155080 and BQ-788. FEBS Lett. 1996;396:238–242
  25. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461–1465
  26. Sirvio ML, Metsarinne K, Saijonmaa O, Fyhrquist F. Tissue distribution and half-life of 125I-endothelin in the rat: Importance of pulmonary clearance. Biochem Biophys Res Commun. 1990;167:1191–1195
  27. Wagner OF, Vierhapper H, Gasic S, Nowotny P, Waldhausl W. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest. 1992;22:277–282
  28. Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C, et al. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol. 2008;294:F1185–F1194
  29. Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract. 2008;4:490–501
  30. Treiber FA, Jackson RW, Davis H, Pollock JS, Kapuku G, Mensah GA, et al. Racial differences in endothelin-1 at rest and in response to acute stress in adolescent males. Hypertension. 2000;35:722–725
  31. Ergul S, Ergul A, Hudson JA, Puett D, Wieman BM, Durham MD, et al. The effect of regulation of high blood pressure on plasma endothelin-1 levels in blacks with hypertension. Am J Hypertens. 1998;11:1381–1385

 Supported by grants HL051547 and DK046107 from the National Institutes of Health, and a grant from the Pennsylvania Department of Public Health. The Pennsylvania Department of Public Health disclaims responsibility for any analyses, interpretations, or conclusions.

 Conflict of Interest: none.

PII: S1933-1711(10)00161-0

doi: 10.1016/j.jash.2010.07.004

Journal of the American Society of Hypertension
Volume 4, Issue 5 , Pages 227-235 , September 2010

Article Tools

* Image Usage & Resolution